We Analyzed the Future Direction of Recro Pharma Inc. (REPH), Here is What We Found – News Heater
Home  »  Business   »  We Analyzed the Future Direction of Recro Pharma I...

We Analyzed the Future Direction of Recro Pharma Inc. (REPH), Here is What We Found

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp

Recro Pharma Inc. (NASDAQ:REPH) went up by 6.90% from its latest closing price compared to the recent 1-year high of $5.29. The company’s stock price has collected -11.93% of loss in the last five trading sessions. Press Release reported on 11/10/21 that Virpax Advances Envelta(TM) Development with NCATS Under CRADA Agreement

Is It Worth Investing in Recro Pharma Inc. (NASDAQ :REPH) Right Now?

Plus, the 36-month beta value for REPH is at 1.06. Opinions of the stock are interesting as 3 analysts out of 3 who provided ratings for Recro Pharma Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


The average price from analysts is $5.50, which is $3.95 above the current price. REPH currently public float of 43.30M and currently shorts hold a 1.55% ratio of that float. Today, the average trading volume of REPH was 321.46K shares.

REPH’s Market Performance

REPH stocks went down by -11.93% for the week, with a monthly drop of -12.43% and a quarterly performance of -38.49%, while its annual performance rate touched -33.19%. The volatility ratio for the week stands at 9.14% while the volatility levels for the past 30 days are set at 6.67% for Recro Pharma Inc.. The simple moving average for the period of the last 20 days is -12.75% for REPH stocks with a simple moving average of -37.86% for the last 200 days.

Analysts’ Opinion of REPH

Many brokerage firms have already submitted their reports for REPH stocks, with Stephens repeating the rating for REPH by listing it as a “Overweight.” The predicted price for REPH in the upcoming period, according to Stephens is $14 based on the research report published on October 17th of the previous year 2019.

Janney, on the other hand, stated in their research note that they expect to see REPH reach a price target of $13. The rating they have provided for REPH stocks is “Buy” according to the report published on January 31st, 2019.

Oppenheimer gave a rating of “Outperform” to REPH, setting the target price at $19 in the report published on February 14th of the previous year.

REPH Trading at -17.75% from the 50-Day Moving Average

After a stumble in the market that brought REPH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -70.70% of loss for the given period.

Volatility was left at 6.67%, however, over the last 30 days, the volatility rate increased by 9.14%, as shares sank -18.42% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -28.90% lower at present.

During the last 5 trading sessions, REPH fell by -11.93%, which changed the moving average for the period of 200-days by -62.47% in comparison to the 20-day moving average, which settled at $1.7590. In addition, Recro Pharma Inc. saw -45.61% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at REPH starting from Miller James Charles, who purchase 1,000 shares at the price of $1.69 back on Nov 17. After this action, Miller James Charles now owns 27,923 shares of Recro Pharma Inc., valued at $1,689 using the latest closing price.

Lake Ryan David, the Chief Financial Officer of Recro Pharma Inc., purchase 1,212 shares at $1.65 during a trade that took place back on Nov 12, which means that Lake Ryan David is holding 374,385 shares at $1,997 based on the most recent closing price.

Stock Fundamentals for REPH

Current profitability levels for the company are sitting at:

  • -9.59 for the present operating margin
  • +14.71 for the gross margin

The net margin for Recro Pharma Inc. stands at -41.36. The total capital return value is set at -6.37, while invested capital returns managed to touch -27.73. Equity return is now at value -172.10, with -17.50 for asset returns.

>> 7 Top Picks for the Post-Pandemic Economy <<

When we switch over and look at the enterprise to sales, we see a ratio of 2.52, with the company’s debt to enterprise value settled at 0.71. The receivables turnover for the company is 3.36 and the total asset turnover is 0.62. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.93.

Sign up for our FREE Newsletter and get:

Leave a Comment

Your email address will not be published. Required fields are marked *

Sign up for our FREE Newsletter and get:

A Lesson to Learn: Deere & Company (DE)

Deere & Company (NYSE:DE) went up by 2.66% from its latest closing price compared to the recent 1-year high of $400.34. The company’s stock price

Heading

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam

Heading

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam